Locket Healthcare Signs Distribution Agreement for Cartilage Regeneration Platform in Italy

[Asia Economy Reporter Hyungsoo Park] Rokit Healthcare announced that it has signed a local distribution contract with Italy's Lamonea. The contract is worth approximately 34 billion KRW (24 million USD) over five years.

Lamonea, with 40 years of experience, is a medical device distributor with a network in Italy. Rokit Healthcare will introduce its cartilage regeneration treatment platform and medical 3D printers to Italian hospitals.

Rokit Healthcare conducted animal clinical trials at Harvard Medical Center in the United States and completed human clinical trials in Egypt. To secure a sales network in the European market, it is strengthening marketing efforts centered on Spain, Hungary, and Italy. By entering the Italian market, it has established a foothold to expand into the entire European market, including Spain and Hungary.

Rokit Healthcare has secured numerous research achievements in cartilage regeneration. Since 2012, through preclinical studies with Harvard Medical School and Seoul National University College of Veterinary Medicine, it has proven the safety and efficacy of its cartilage regeneration treatment platform. Since 2019, clinical trials have been conducted with the orthopedic team at Assiut University Hospital in Egypt on 10 osteoarthritis patients. The trial concluded last February. Improvements in knee pain and function were confirmed starting three months after surgery.

Professor Mohamed of Assiut University Hospital, who led the clinical trials, said, "I observed all stages from diagnosis of clinical participants to symptom improvement after surgery," adding, "Significant improvements in joint function and pain were confirmed from the third month after surgery." He further stated, "At 12 months, arthroscopic examination of the surgical site showed a structure similar to normal hyaline cartilage."

Kershin Annika Svensson, CEO of Lamonea, said, "We believe the contract with Rokit will bring great value to both companies," and added, "We are pleased to open a new horizon in the Italian medical community together with Rokit."

Jakyum Koo, President of Rokit Healthcare in charge of cartilage and hospital platforms, introduced, "We are currently maintaining continuous communication with major companies in other regions such as Spain and Egypt," and said, "We expect additional distribution contracts." He continued, "As the results of domestic preliminary clinical evaluations started last year accumulate, we are proving our technological capabilities," and stated, "We will strive to enter overseas markets as soon as possible."

This content was produced with the assistance of AI translation services.